Britta Kehden

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.

CD20 expression dynamics in adult B-cell acute lymphoblastic leukemia and impact on anti-CD20 treatment.

Journal: Journal of hematology & oncology

Published: March 31, 2026

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood

Published: August 14, 2025

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood

Published: August 14, 2025

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.

ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study.

Journal: Leukemia

Published: March 28, 2025

NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.

NGS-based IG/TR gene rearrangement profiling in acute lymphoblastic leukemia: age dependence of immunogenetic maturation.

Journal: Blood

Published: October 08, 2024

Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia.

Next-generation sequencing and high DNA input identify previously missed measurable residual disease in peripheral blood of B-cell precursor acute lymphoblastic leukaemia.

Journal: British journal of haematology

Published: July 10, 2024

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.

Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 14, 2023

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.

Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia.

Journal: Leukemia

Published: July 30, 2023

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.

Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.

Journal: Blood

Published: June 01, 2022

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.

MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.

Journal: Leukemia

Published: March 25, 2019

Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia.

Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia.

Journal: Leukemia

Published: March 08, 2019

Required Effekt Sizes of Preventive Measures for Overweight in Children and Adolescents

Required Effekt Sizes of Preventive Measures for Overweight in Children and Adolescents

Journal: Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))

Published: March 05, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026